Ampersand closes USD 1.2bn healthcare fund for US, EU deployment

The fund, Ampersand 2022 ("AMP-22") Limited Partnership, held a single close just three months after it launched. 

The GP said in a statement it aims to make majority and minority investments in companies with USD 10m to USD 100m in revenues and positive EBITDA.

Ampersand typically deploys tickets of between USD 10m and USD 50m targeting primary buyouts from entrepreneurs, according to its LinkedIn page.

Within healthcare, the fund typically invests in pharmaceutical services, contract manufacturing, laboratory testing services and products, and specialty pharma. 

The new fundraise comes amid an expected record-breaking year for healthcare specialist fundraises and large-cap generalist GPs acquiring stakes in specialist healthcare investors. 

While the investor is based in Boston, US, it has offices in Amsterdam and has recently made a hiring push in Europe. 

The firm poached Hidde Van Kerckhoven after six years at Gimv in June as VP in the Netherlands, as well as Benoit Bouche from the pharmaceutical industry in France in April, according to LinkedIn. 

Ampersand currently has six portfolio companies in Europe, according to its website. Most recently, it made a growth investment in German manufacturer of nucleic acid purification solutions, BioEcho.

Its portfolio company Alliance Pharma also carved out the Drug Development Solutions (DDS) of UK-based LGC.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyout
• Healthcare
• GPs
• Benelux
• Ampersand Capital
• healthcare